# Forensic Dossier: Study Forensics: Rapamycin for human longevity — promise vs proof

**Run ID:** `full27_study-forensics-031_Claude_Haiku_c559c5`  
**Task:** study-forensics-031 | study_forensics | hard | study_forensics  
**Timestamp:** 2026-04-08T18:03:07.324768+00:00  
**Task Family:** solid  
**Trap Type:** overflagging_cautious_early_data  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **72.6/100** (margin: 0.0)
**Failure modes:** named_not_explained, unsupported_intermediate_step, unused_assumption
**Forensic flags:** 5
**Consistency findings:** 7
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.7/8 | 4.8/8 | 4.3/6 | 3.9/6 | 5.2/6 | 5.6/8 | 8.0/8 | 1.5/10 | 8.5/10 | **72.6/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `solid` [+] (gold: `solid`)
**Finding Recall:** 100%
**Matched Findings:** evidence_matches_claim, cautious_scope_control
**Extra Findings:** none_or_minor, conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 6

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "solid"


## Forensic Flags

### Claude Haiku

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "solid"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "solid"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"
- **[MINOR]** `study_forensics_overflagging`: Agent raised extra findings in solid case: none_or_minor, conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "solid"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 1.2/8
  - (+) `final_answer`: "solid"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 6
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 4.8/8
  - (+) `steps[5]`: "6. CLASSIFICATION DECISION: The text correctly identifies the evidence-tier mismatch and does not attempt to bridge it w"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 0/6 steps contribute

**Assumption Discipline:** 4.3/6
  - (+) `assumptions[1]`: "The human trial described is indeed the 'first well-designed' trial for this indication."
    _Most substantive assumption_
  - (-) `assumptions[3]`: "The text is reporting on current scientific consensus, not a single outlier study."
    _Declared but unused in reasoning_
  - Note: 4/4 substantive assumptions
  - Note: 1 unused assumption(s)

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[2]`: "Whether there are other human trials or biomarker studies not mentioned here that might partially bridge the gap (the te"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - Note: 3 uncertainties (3 substantive)
  - Note: Confidence 0.92

**Alternative Hypothesis Quality:** 5.2/6
  - (+) `alternative_hypotheses[0]`: "Could this be mechanism_vs_evidence? Only if the text were implying human benefit despite the tier gap. But it explicitl"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 1/2 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[1]`: "Did I mistake cautious language for decorative hedging? No. The caveats here are substantive and directly address the ev"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.70, 606 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 3 full / 3


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "solid"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "solid"
  - _Impacts: support_strength, structural_reasoning_

**STYLISTIC:**
- **Unused Assumption** `[HEURISTIC]`: Assumption 'The text is reporting on current scientific consensus, not a...' is declared but not referenced in reasoning
  - `assumptions[3]`: "The text is reporting on current scientific consensus, not a single outlier study."
  - _Impacts: assumption_discipline_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/9 content words)
  - `key_claims[0]`: "Mouse lifespan extension (10–25%) is reliable and replicated — this is strong animal evidence."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/16 content words)
  - `key_claims[1]`: "The first well-designed human trial failed its primary endpoint (abdominal fat reduction) and did no"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/15 content words)
  - `key_claims[2]`: "Experts caution that no clinical evidence shows rapamycin slows aging in humans — this is an explici"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/12 content words)
  - `key_claims[3]`: "Off-label use carries risks, especially for those with active cancer — this is a safety note that ap"
- **[WARN]** `[HEURISTIC]` `unused_assumption`: Assumption 4 appears unused in reasoning or answer
  - `assumptions[3]`: "The text is reporting on current scientific consensus, not a single outlier study."
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "Could this be overclaim? Only if the text were using promotional language or stating human benefit a"
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "solid"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 11690ms

**Final Answer:** solid

**Confidence:** 0.92

**Assumptions:**
- The text accurately represents the mouse lifespan studies as replicated and reliable.
- The human trial described is indeed the 'first well-designed' trial for this indication.
- The primary endpoint (abdominal fat reduction) is a reasonable proxy for aging benefit.
- The text is reporting on current scientific consensus, not a single outlier study.

**Reasoning Steps:**
1. 1. EVIDENCE TIER IDENTIFICATION: The strongest evidence presented is from animal models (mice showing 10–25% lifespan extension, replicated). The human evidence is limited: one well-designed trial with a failed primary endpoint and modest secondary outcomes, no direct aging biomarkers tested.
2. 2. CONCLUSION TIER IDENTIFICATION: The text discusses off-label human use for aging, implying a human therapeutic claim.
3. 3. BRIDGE GAP ANALYSIS: There is a clear tier mismatch — animal lifespan data does not directly translate to human aging benefit. The human trial failed its primary endpoint and did not measure biological aging.
4. 4. HEDGE QUALITY CHECK: The text explicitly states 'no clinical evidence yet shows rapamycin slows aging in people' and notes that 'the study did not test whether the drug slows biological aging.' These are strong, accurate caveats that directly acknowledge the evidence gap.
5. 5. RHETORICAL TONE: The text is analytical and cautious. It does not use promotional language ('breakthrough,' 'transforms,' 'confirms effectiveness'). It reports facts (mouse data, trial results, expert caution) without inflating claims.
6. 6. CLASSIFICATION DECISION: The text correctly identifies the evidence-tier mismatch and does not attempt to bridge it with unsupported claims. The caveats are substantive, not decorative. The conclusion stays within the bounds of what the evidence supports: mice show lifespan extension; humans show no aging benefit yet; off-label use carries risks. This is a solid, well-hedged summary.

**Key Claims:**
- Mouse lifespan extension (10–25%) is reliable and replicated — this is strong animal evidence.
- The first well-designed human trial failed its primary endpoint (abdominal fat reduction) and did not test biological aging — this is honest reporting of a negative result.
- Experts caution that no clinical evidence shows rapamycin slows aging in humans — this is an explicit, substantive caveat that correctly identifies the evidence gap.
- Off-label use carries risks, especially for those with active cancer — this is a safety note that appropriately contextualizes the uncertainty.

**Alternative Hypotheses:**
- Could this be mechanism_vs_evidence? Only if the text were implying human benefit despite the tier gap. But it explicitly denies that claim ('no clinical evidence yet shows rapamycin slows aging in people'), so the bridge is not being crossed.
- Could this be overclaim? Only if the text were using promotional language or stating human benefit as fact. It does neither; it reports the mouse data, the failed trial, and expert caution.

**Uncertainties:**
- Whether the mouse lifespan studies are truly as robust as the text suggests (though the claim of replication across labs is a good sign).
- Whether the human trial's failure on abdominal fat is truly the 'first well-designed' trial (the text asserts this, but I cannot verify independently).
- Whether there are other human trials or biomarker studies not mentioned here that might partially bridge the gap (the text does not claim to be exhaustive).

**Self-Verification:**
- Did I overread the text as making unsupported claims? No. The text explicitly denies that human aging benefit is established.
- Did I mistake cautious language for decorative hedging? No. The caveats here are substantive and directly address the evidence gap.
- Did I miss an overclaim? No. The text does not use promotional language or state human benefit as fact.
- Did I correctly identify the tier mismatch? Yes. Animal data ≠ human therapeutic evidence. But the text acknowledges this.
- Is this a solid study summary? Yes. It reports the evidence accurately, identifies the gap, and does not cross it without support.

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.7/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.3/6 `#######...`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 5.2/6 `########..`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **72.6/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.7/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.3/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (5.2/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 11.7s | 72.6/100 | 6.2 |

Failure modes observed: named_not_explained, unsupported_intermediate_step, unused_assumption.
